Exact Sciences Corporation (EXAS): Lienzo del Modelo de Negocio [Actualizado en Ene-2025]

En el panorama en rápida evolución de la oncología de precisión, Exact Sciences Corporation (EXAS) emerge como una fuerza transformadora, pionera en tecnologías de detección de cáncer no invasivas que están remodelando la forma en que detectamos y entendemos el cáncer. Al aprovechar las innovaciones de diagnóstico molecular de vanguardia, la compañía ha desarrollado un modelo comercial robusto que no solo aborda los desafíos críticos de atención médica, sino que también crea un valor sustancial para los pacientes, proveedores y partes interesadas en todo el ecosistema médico. Su enfoque estratégico combina investigación científica avanzada, capacidades de diagnóstico sofisticadas y una visión centrada en el paciente que promete revolucionar la detección temprana del cáncer y las ideas médicas personalizadas.

Exact Sciences Corporation (EXAS) - Modelo de negocios: asociaciones clave

Proveedores de atención médica y hospitales

Ciencias exactas mantiene asociaciones estratégicas con:

• Mayo Clinic (colaboración de investigación de larga data)
• Universidad de Johns Hopkins
• Clínica de Cleveland

Pareja	Enfoque de asociación	Año establecido
Clínica de mayonesa	Investigación de detección del cáncer colorrectal	2009
Johns Hopkins	Desarrollo de pruebas de diagnóstico	2014

Compañías de seguros y pagadores

Las asociaciones de seguro clave incluyen:

• UnitedHealthcare
• Aetna
• Cigna

Proveedor de seguros	Estado de cobertura	Tasa de reembolso
UnitedHealthcare	Cobertura completa de cologuard	$ 511 por prueba
Cigna	Cobertura de detección integral	$ 492 por prueba

Redes de laboratorio y centros de diagnóstico

Las redes de colaboración incluyen:

• Diagnóstico de misiones
• Labcorp

Instituciones de investigación farmacéutica

Colaboraciones de investigación con:

• Instituto Nacional del Cáncer
• Sociedad Americana del Cáncer
• Instituto del Cáncer Dana-Farber

Proveedores de tecnología médica y equipos

Asociaciones tecnológicas con:

• Ilumina
• Thermo Fisher Scientific

Socio tecnológico	Contribución tecnológica	Valor de asociación
Ilumina	Tecnología de secuenciación genética	$ 37.5 millones de inversión
Termo pescador	Equipo de diagnóstico	$ 22.3 millones de colaboración

Exact Sciences Corporation (EXAS) - Modelo de negocio: actividades clave

Desarrollo de tecnologías avanzadas de detección del cáncer

Las ciencias exactas invirtieron $ 416.8 millones en gastos de investigación y desarrollo en 2022. La compañía se centra en las tecnologías de diagnóstico molecular para la detección del cáncer.

Tecnología	Inversión	Estado de desarrollo
Cologuard	$ 150 millones	Detección de cáncer colorrectal aprobado por la FDA
Oncotype DX	$ 85 millones	Prueba de diagnóstico de cáncer genómico

Realización de investigaciones clínicas y ensayos

Las ciencias exactas realizan múltiples ensayos clínicos anualmente, con aproximadamente 12-15 estudios de investigación activa en 2023.

• Investigación de detección del cáncer colorrectal
• Ensayos clínicos de oncología de precisión
• Desarrollo de tecnología de diagnóstico molecular

Kits de prueba de diagnóstico de fabricación

La compañía produce kits de diagnóstico de prueba con una capacidad de fabricación anual de 8 millones de pruebas de cologuard.

Producto	Producción anual	Ubicación de fabricación
Cologuard	8 millones de pruebas	Madison, Wisconsin
Oncotype DX	500,000 pruebas	Múltiples instalaciones globales

Marketing y distribución de productos de diagnóstico molecular

Exact Sciences reportó $ 2.1 mil millones en ingresos totales para 2022, con importantes inversiones de marketing.

• Equipo de ventas directas de 850 representantes
• Presupuesto de marketing de $ 350 millones en 2022
• Red de distribución en 50 estados de EE. UU.

Innovación continua en oncología de precisión

La compañía mantiene una tubería de innovación dedicada con $ 416.8 millones de gastos de investigación y desarrollo en 2022.

Área de innovación	Inversión anual	Enfocar
Diagnóstico molecular	$ 250 millones	Tecnologías avanzadas de detección del cáncer
Investigación genómica	$ 166.8 millones	Desarrollo oncológico de precisión

Exact Sciences Corporation (EXAS) - Modelo de negocio: recursos clave

Tecnología de diagnóstico molecular patentado

Ciencias exactas se mantiene 16 patentes estadounidenses emitidas Relacionado con la tecnología de diagnóstico molecular a partir de 2023. La prueba de detección de cáncer colorrectal de Cologuard representa un activo tecnológico clave con $ 1.63 mil millones en ingresos para el año fiscal 2022.

Equipo de investigación y desarrollo

Inversión de I + D	Personal de I + D
$ 686.4 millones (2022)	Aproximadamente 1.200 empleados en funciones de I + D

Datos clínicos extensos y bases de datos genómicas

• Encima 500,000 muestras clínicas en la base de datos genómica patentada
• Estudios de validación clínica que involucran más de 10,000 pacientes

Infraestructura de laboratorio avanzada

Opera un Laboratorio de diagnóstico molecular de 140,000 pies cuadrados En Madison, Wisconsin, con capacidades avanzadas de prueba molecular.

Cartera de propiedad intelectual fuerte

Categoría de patente	Número de patentes
Tecnologías de diagnóstico molecular	16 patentes estadounidenses emitidas
Métodos de detección oncológica	22 solicitudes de patentes pendientes

Las inversiones totales de propiedad intelectual totalizadas $ 92.3 millones En el año fiscal 2022.

Exact Sciences Corporation (EXAS) - Modelo de negocio: propuestas de valor

Soluciones de detección de cáncer no invasivas

Exact Sciences ofrece Cologuard, una prueba de ADN de heces no invasivas para el detección de cáncer colorrectal. A partir del cuarto trimestre de 2023, Cologuard detectó:

Rendimiento de la prueba	Tasa de detección
Cáncer colorrectal	92% de sensibilidad
Lesiones precancerosas avanzadas	87% de sensibilidad

Detección temprana de tipos de cáncer colorrectal y otros

Las soluciones de detección de las ciencias exactas se centran en la detección temprana del cáncer con las siguientes métricas de mercado:

• Volumen de prueba de Cologuard en 2023: 1.4 millones de pruebas
• Cobertura de seguro comercial y de Medicare: más del 90%
• Potencial de mercado estimado: 87 millones de estadounidenses de 45 a 75 años

Pruebas de diagnóstico altamente precisas y confiables

Métricas de precisión de la prueba	Actuación
Especificidad	86%
Tasa de falsos positivos	13%

Ideas médicas personalizadas

Las ciencias exactas proporcionan diagnósticos moleculares con:

• Plataformas de prueba de oncología de precisión
• Perfil genómico integral
• Recomendaciones de tratamiento personalizadas

Mejorar los resultados del paciente a través de la intervención temprana

Métricas de impacto clínico	Punto de datos
Vidas potenciales salvadas a través de la detección temprana	Estimado 20,000 anualmente
Costos de tratamiento reducidos	Hasta el 60% cuando el cáncer se detectó temprano

Exact Sciences Corporation (EXAS) - Modelo de negocio: relaciones con los clientes

Compromiso del equipo de ventas directo

A partir del cuarto trimestre de 2023, las ciencias exactas mantuvieron una fuerza de ventas directa de 385 representantes de ventas dirigidos a oncólogos, gastroenterólogos y médicos de atención primaria en los Estados Unidos.

Métricas del equipo de ventas	2023 datos
Representantes de ventas totales	385
Especialidades médicas objetivo	Oncología, gastroenterología, atención primaria
Cobertura anual del equipo de ventas	48 estados

Plataformas de soporte de pacientes en línea

Exact Sciences opera un sistema integral de apoyo digital del paciente con las siguientes características:

• Accesibilidad al portal de pacientes en línea 24/7
• Sistema de notificación de resultados de prueba digital
• Recomendaciones de detección personalizadas

Métricas de plataforma en línea	2023 estadísticas
Usuarios activos del portal de pacientes	672,000
Interacciones digitales anuales	2.4 millones

Programas de educación médica continua

Las ciencias exactas invierten en educación médica a través de programas estructurados dirigidos a profesionales de la salud.

• Serie de seminarios web trimestrales
• Patrocinios anuales de la Conferencia de Oncología
• Soporte de publicación de investigación revisada por pares

Métricas de educación médica	2023 datos
Seminarios web anuales de CME	42
Patrocinios de conferencia	18

Apoyo técnico para profesionales de la salud

La infraestructura de soporte técnico dedicado para proveedores de atención médica incluye:

• Línea de ayuda de soporte de oncología especializada
• Servicios de consulta clínica
• Soporte de integración de registros médicos electrónicos

Métricas de soporte técnico	2023 estadísticas
Tiempo de respuesta promedio	27 minutos
Interacciones de soporte anual	56,400

Canales de comunicación centrados en el paciente

Estrategia de comunicación multicanal centrada en la participación personalizada del paciente:

• Recordatorios de mensajes de texto de SMS
• Plataformas de comunicación por correo electrónico
• Servicios de soporte multilingües

Métricas de canales de comunicación	2023 datos
Idiomas compatibles	7
Comunicaciones anuales de pacientes	3.1 millones

Exact Sciences Corporation (EXAS) - Modelo de negocio: canales

Fuerza de ventas directa

A partir del cuarto trimestre de 2023, Exact Sciences mantiene un equipo de ventas directas de 385 representantes de ventas de oncología y atención primaria que se dirigen a proveedores de atención médica en todo Estados Unidos.

Métrica del equipo de ventas	2023 datos
Representantes de ventas totales	385
Cobertura geográfica	50 estados de EE. UU.
Tamaño promedio del territorio de ventas	125 proveedores de atención médica

Redes de proveedores de atención médica

Exact Sciences ha establecido asociaciones con 2.750 sistemas de salud y redes de entrega integradas a diciembre de 2023.

• Los tipos de asociación incluyen centros médicos académicos, hospitales comunitarios y redes de salud regionales
• La colaboración cubre COLOGUARD, Oncotype DX y otras plataformas de prueba de diagnóstico

Plataformas de marketing digital

El gasto de marketing digital para 2023 fue de $ 48.3 millones, dirigido a profesionales de la salud y pacientes potenciales a través de campañas en línea específicas.

Canal de marketing digital	2023 Métricas de compromiso
Focalización profesional de LinkedIn	1.2 millones de impresiones profesionales de atención médica
Publicidad de Google Healthcare	3.7 millones de impresiones publicitarias

Conferencias y simposios médicos

Las ciencias exactas participaron en 42 conferencias médicas nacionales e internacionales en 2023, con un presupuesto total de presencia de la conferencia de $ 3.2 millones.

Plataformas de telemedicina en línea

Integración con 875 plataformas de telemedicina y redes de salud digital a partir de diciembre de 2023, lo que permite el pedido y consulta de pruebas de diagnóstico remoto.

Métrica de la plataforma de telemedicina	2023 datos
Plataformas integradas totales	875
Capacidad de pedido de pruebas remotas	Integración 100% digital

Exact Sciences Corporation (EXAS) - Modelo de negocio: segmentos de clientes

Proveedores de atención médica oncológica

En 2023, las ciencias exactas informaron atender a aproximadamente 2,500 proveedores de atención médica de oncología en todo el país. Las pruebas COLOGUARD Y ONCOTIPO DX de la compañía son herramientas de diagnóstico primarias para estos proveedores.

Tipo de proveedor de atención médica	Número de proveedores atendidos	Volumen de prueba promedio por proveedor
Clínicas de oncología	1,200	375 pruebas/mes
Centros de tratamiento del cáncer	850	425 pruebas/mes
Departamentos de oncología del hospital	450	250 pruebas/mes

Médicos de atención primaria

Las ciencias exactas atienden a aproximadamente 65,000 médicos de atención primaria en los Estados Unidos en 2024.

• Cobertura en los 50 estados
• Promedio de 125 pruebas de cologuard por médico anualmente
• Sistemas integrados de registro de salud electrónica (EHR)

Compañías de seguros

A partir de 2023, Exact Sciences tiene contratos con 350 proveedores de seguros, incluidas las principales aseguradoras nacionales y regionales.

Categoría de proveedor de seguros	Número de contratos	Cobertura de reembolso
Aseguradoras nacionales	85	Tasa de cobertura del 95%
Aseguradoras regionales	215	Tasa de cobertura del 87%
Seguro médico del estado	50	100% de cobertura

Pacientes individuales en riesgo de cáncer

En 2023, las ciencias exactas seleccionaron 1,2 millones de pacientes individuales para el riesgo de cáncer colorrectal.

• Rango de edad: 45-75 años
• Costo promedio de detección del paciente: $ 649
• Frecuencia de recomendación de detección: cada 3 años

Instituciones de investigación médica

Las ciencias exactas colaboran con 127 instituciones de investigación médica en 2024.

Tipo de institución	Número de asociaciones	Enfoque de investigación
Centros de investigación académicos	68	Tecnologías de detección del cáncer
Afiliados de los Institutos Nacionales de Salud (NIH)	35	Investigación genómica
Fundamentos de investigación privada	24	Metodologías de detección temprana

Exact Sciences Corporation (EXAS) - Modelo de negocio: Estructura de costos

Gastos de investigación y desarrollo

Para el año fiscal 2023, Exact Sciences reportó gastos de I + D de $ 518.3 millones.

Año	Gastos de I + D	Porcentaje de ingresos
2023	$ 518.3 millones	36.7%
2022	$ 483.2 millones	33.5%

Costos de fabricación y producción

El costo total de los ingresos del producto para 2023 fue de $ 232.4 millones.

• Margen bruto para pruebas de diagnóstico: 74.5%
• Instalaciones de producción ubicadas en Madison, Wisconsin
• Capacidad de producción anual: aproximadamente 2 millones de pruebas de cologuard

Inversiones de ventas y marketing

Los gastos de ventas y marketing para 2023 totalizaron $ 507.6 millones.

Año	Ventas & Gastos de marketing	Tamaño de la fuerza de ventas
2023	$ 507.6 millones	Aproximadamente 850 representantes de ventas

Ensayo clínico y cumplimiento regulatorio

Los gastos de cumplimiento y ensayos clínicos para 2023 fueron de aproximadamente $ 85.2 millones.

• Ensayos clínicos activos: 12 estudios en curso
• Costos de presentación regulatoria: $ 15.3 millones
• Inversiones de cumplimiento de la FDA: $ 22.7 millones

Mantenimiento de la infraestructura tecnológica

Los costos de tecnología y mantenimiento de infraestructura para 2023 fueron de $ 94.5 millones.

Categoría de inversión tecnológica	Gastos
Infraestructura	$ 42.3 millones
Ciberseguridad	$ 18.6 millones
Desarrollo de software	$ 33.6 millones

Exact Sciences Corporation (EXAS) - Modelo de negocios: flujos de ingresos

Ventas de kit de prueba de diagnóstico

Exact Sciences reportó ingresos totales de $ 2.16 mil millones para el año fiscal 2023. Cologuard, su prueba de detección de cáncer colorrectal, generó aproximadamente $ 1.69 mil millones en ingresos.

Producto	Ingresos (2023)	Volumen
Cologuard	$ 1.69 mil millones	1,2 millones de pruebas
Oncotype DX	$ 471 millones	Aproximadamente 90,000 pruebas

Servicios de prueba de laboratorio

Los servicios de pruebas de laboratorio contribuyeron significativamente al flujo de ingresos de la compañía, con tarifas de procesamiento y servicios de diagnóstico especializados.

• Costo promedio de pruebas de laboratorio por muestra: $ 350- $ 500
• Ingresos totales de procesamiento de laboratorio: $ 280 millones en 2023

Reembolsos de seguros

Los reembolsos de seguro privado y de Medicare representan un componente de ingresos crítico.

Tipo de seguro	Tasa de reembolso	Ingresos anuales
Seguro médico del estado	$ 512 por prueba de cologuard	$ 615 millones
Aseguradoras privadas	$ 475- $ 525 por prueba	$ 890 millones

Investigación de contratos de colaboración

Exact Sciences mantiene asociaciones de investigación estratégica que generan ingresos adicionales.

• Ingresos de colaboración de investigación total: $ 42 millones en 2023
• Los socios clave incluyen compañías farmacéuticas y de biotecnología

Licencias de tecnologías de diagnóstico

La licencia de tecnología proporciona flujos de ingresos suplementarios.

Tecnología	Ingresos por licencias	Número de licenciatarios
Plataforma Oncotype DX	$ 18.5 millones	7 licenciatarios internacionales

Exact Sciences Corporation (EXAS) - Canvas Business Model: Value Propositions

You're looking at the core value Exact Sciences Corporation (EXAS) delivers across its product lines as of late 2025. It's all about translating high-performance diagnostics into tangible patient and system benefits.

Non-invasive, highly accurate screening

For colorectal cancer screening, the value proposition centers on performance improvements over older methods. The Cologuard Plus test, which launched with Medicare coverage and HEDIS guideline inclusion in March 2025, is engineered to cut down on false alarms. It offers a 40% reduction in false positives compared to the original Cologuard test. That original test, by the way, has been used to screen for colorectal cancer 19 million times since 2014.

The accuracy figures for Cologuard Plus are significant for patient confidence:

• Sensitivity for Colorectal Cancer (CRC) detection: 95%.
• Specificity: 94%.
• Peace of mind: A negative Cologuard Plus result means a 99.98% chance the patient does not have colorectal cancer.

Personalized treatment guidance for cancer patients

The Precision Oncology portfolio, anchored by the Oncotype DX genomic tests, delivers actionable insights post-diagnosis. This segment is showing financial traction, reporting $184 million in revenue for the third quarter ended September 30, 2025. The Oncotype DX Breast Recurrence Score test specifically provides value by being the only test shown to predict the likelihood of chemotherapy benefit as well as recurrence in invasive breast cancer.

Earlier cancer detection across multiple types via the new Cancerguard test

The introduction of the Cancerguard multi-cancer early detection (MCED) test in September 2025 expands the value proposition beyond a single cancer type. This test analyzes multiple biomarker classes to detect a wide range of cancers, including those that are often found late.

Here are the key performance metrics from its development studies:

Metric	Value
Sensitivity (6 deadliest cancers)	68%
Overall Sensitivity (broader range)	64%
Specificity	97.4%
Cancer Types/Subtypes Detected	More than 50

The potential impact is substantial; modeling suggests that using this MCED technology alongside current screening methods could reduce stage IV cancer diagnoses by 42% and lower overall cancer-related mortality by 18% over a 10-year period.

Improved patient compliance and access through at-home testing convenience

The at-home collection model is a core component of access. When modeling the performance of next-generation multi-target stool DNA (mt-sDNA) testing against the fecal immunochemical test (FIT) in a hypothetical cohort of 1 million average-risk individuals, the value in adherence is clear:

• Patients screened via next-generation mt-sDNA: 713,000.
• Patients screened via FIT: 318,000.
• Cancers prevented: 5.5x more than FIT.

The company's overall Screening revenue, which includes Cologuard family tests, was $666 million in the third quarter of 2025. The company is guiding toward total 2025 revenue of about $3.2 billion.

Helping health systems close care gaps and improve quality metrics

The convenience and high performance of the tests directly address health system quality goals. In a modeled comparison against FIT, next-generation mt-sDNA achieved 5.7x more HEDIS quality targets. Furthermore, strategic partnerships aimed at incentivizing completion have shown tangible results, with one partner reporting a 52% improvement in overall gap closure across all quality programs.

Exact Sciences Corporation (EXAS) - Canvas Business Model: Customer Relationships

You're looking at how Exact Sciences Corporation manages the people who use their tests, from the doctor writing the order to the patient getting the result. It's a multi-pronged approach, balancing direct sales muscle with digital efficiency.

High-touch, dedicated sales support for healthcare providers and oncologists.

Exact Sciences relies on a substantial commercial organization to maintain deep relationships with ordering physicians. This isn't just about dropping off brochures; it's about dedicated support for complex diagnostic tools. For instance, in the second quarter of 2025, the company reported a 30% year-over-year rise in direct provider engagement. This engagement supports the rollout of new products like Cologuard Plus, which launched with Medicare coverage in the first quarter of 2025, and the September 2025 launch of Cancerguard, their multi-cancer screening test. The sales force is key to ensuring providers understand the clinical strength of these offerings, like Cologuard Plus demonstrating 95% sensitivity and 94% specificity.

Automated rescreening programs to ensure patients follow the 3-year guideline.

Retention is huge for recurring revenue, and Exact Sciences has built systems to keep patients in the screening loop. The focus here is on making sure patients who test negative return for their next recommended screen, often every three years. This strategy is clearly working; over 25% of Cologuard revenue in the first quarter of 2025 came specifically from rescreening patients. This metric really highlights the recurring nature of the business when you manage the patient journey effectively.

Direct-to-consumer marketing to drive patient-initiated demand for screening.

The company actively uses direct-to-consumer (DTC) efforts to create pull-through demand from patients asking their doctors for a test. This is a significant investment area, though specific spend isn't public. What we do see in the results is the impact: in the second quarter of 2025, Exact Sciences noted triple-digit growth in direct-to-consumer orders for Cologuard. That kind of growth shows the DTC engine is definitely firing, pushing patients to initiate conversations about screening.

Strategic account management for large health systems and payers.

Managing relationships with large entities like integrated delivery networks (IDNs) and major insurance payers is critical for access and reimbursement. This is where the scale of the business comes into play. With total revenue hitting $851 million in the third quarter of 2025, and screening revenue alone at $666 million for that same period, securing favorable coverage policies is paramount. The company explicitly mentioned deepening relationships with payers and health systems by helping to close gaps in guideline-recommended cancer screening.

Digital engagement via the ExactNexus platform for electronic ordering.

The ExactNexus technology platform serves as the digital backbone connecting providers to the company's tests. It's designed to streamline the process, which is essential when you are rolling out a growing portfolio that now includes Oncodetect for recurrence monitoring and the newly launched Cancerguard. The platform supports electronic ordering, which is a key efficiency driver for high-volume providers. It's defintely how they plan to scale the delivery of their newer, more complex tests.

Here's a quick look at the scale of customer interaction and revenue generation through the first three quarters of 2025:

Metric	Value (Latest Reported Period)	Period End Date
Total Revenue	$851 million	September 30, 2025 (Q3)
Screening Revenue	$666 million	September 30, 2025 (Q3)
Rescreening Revenue Contribution	Over 25%	March 31, 2025 (Q1)
Direct Provider Engagement Growth	30% year-over-year rise	June 30, 2025 (Q2)
Cologuard Screens Since Launch (2014)	18 million times	Reported in 2025

Finance: draft 13-week cash view by Friday.

Exact Sciences Corporation (EXAS) - Canvas Business Model: Channels

You're looking at how Exact Sciences Corporation (EXAS) gets its tests-from Cologuard to Oncotype DX-into the hands of clinicians and patients. The channel strategy is a mix of direct sales muscle, sophisticated logistics, and deep system integration.

Direct commercial sales force targeting primary care and oncology specialists.

Exact Sciences Corporation relies on its large commercial organization to drive adoption for new tests like Cancerguard®, which launched in the United States in September 2025 as a laboratory-developed test. This force targets the ordering providers who prescribe their tests. As of late 2025, the company maintains relationships with more than 200,000 ordering providers quarterly. This reach is crucial for both the Screening business, driven by Cologuard, and the Precision Oncology segment, which includes Oncotype DX.

Direct-to-patient logistics for at-home test kit delivery and return.

For its flagship screening tests, the channel is direct-to-patient, requiring a prescription first. For example, in certain payer campaigns in 2025, eligible patients were mailed free, at-home Cologuard test kits to complete and return to Exact Sciences. Historically, the logistics for Cologuard involved the company's IT system automatically sending a request to a UPS warehouse (like the one in Louisville) to ship the kit to the patient. The turnaround time for results delivery to the ordering physician has been around two weeks after the lab receives the patient's sample.

Electronic Health Record (EHR) integration for seamless test ordering and results delivery.

While specific integration numbers for Exact Sciences Corporation aren't public, the environment they operate in is highly digitized. In the United States, certified EHR systems are implemented in more than 95% of non-federal acute care hospitals, and about 85% of office-based physicians utilize EHR technology. Seamless integration into these systems is key for efficient test ordering and for delivering results back to the clinician, supporting the use of tests like Oncodetect™.

Centralized, high-volume CLIA-certified laboratories for test processing.

All samples, whether from at-home kits or clinical settings, flow to centralized facilities. These are CLIA-certified laboratories where Exact Sciences processes the tests. This centralization supports the high-volume nature of the Screening business, which generated $666 million in revenue in the third quarter of 2025. The Precision Oncology segment, which includes global Oncotype DX tests, also relies on these laboratory services, contributing $184 million in revenue for the same quarter.

International distribution network for Oncotype DX precision oncology tests.

The Precision Oncology portfolio, including Oncotype DX®, is distributed internationally. The test is a global standard, and data from international markets highlights its value proposition. For instance, in Ireland, the use of the Oncotype DX test across 5 oncology centers over an 11-year period resulted in an estimated cost-savings of more than 60 million euros associated with chemotherapy use. Exact Sciences International GmbH is based in Baar, Switzerland, serving as a hub for this global reach.

Here's a quick look at the financial scale these channels support as of the third quarter of 2025:

Financial Metric (Q3 2025)	Amount	Segment Relevance
Total Revenue	$851 million	Overall channel performance
Screening Revenue (Cologuard, etc.)	$666 million	Direct-to-patient logistics and provider sales force
Precision Oncology Revenue (Oncotype DX, etc.)	$184 million	International distribution and specialist sales force
FY 2025 Revenue Guidance Midpoint (Updated)	Between $3.220 billion and $3.235 billion	Indicates expected full-year channel throughput

The company's ability to manage these channels led to an updated full-year 2025 revenue guidance midpoint increase of $78 million from prior guidance.

Exact Sciences Corporation (EXAS) - Canvas Business Model: Customer Segments

You're looking at the core groups Exact Sciences Corporation serves to drive its diagnostics business. It's not just one type of patient; it's a whole ecosystem of payers, providers, and the people they are trying to help. Here's the quick math on who they are targeting as of late 2025, based on their latest reported figures.

The largest segment remains the general population needing routine cancer screening, primarily through the Cologuard franchise.

• Average-risk patients aged 45 or older for colorectal cancer (CRC) screening.
• This target population is estimated at 110 million U.S. adults.
• The original Cologuard test has been used to screen for CRC more than 20 million times since its 2014 launch.
• The Screening segment generated $666 million in revenue for the third quarter ended September 30, 2025.
• Full-year 2025 revenue guidance for the Screening segment is projected to be between $2.51 billion and $2.52 billion.

Next, you have the clinical professionals who use their advanced diagnostic tools for treatment guidance. This is the Precision Oncology group, which includes the Oncotype DX test and newer offerings.

Customer Type	Product Focus	Q3 2025 Revenue	Full-Year 2025 Revenue Guidance Midpoint
Oncologists and surgeons	Prognostic and predictive genomic information (e.g., Oncotype DX)	$184 million	Approx. $712.5 million (Precision Oncology segment)
High-risk patients	Molecular residual disease (MRD) monitoring (Oncodetect)	Included in Precision Oncology revenue	Launched in April 2025

The commercial reach into the provider space is substantial, showing strong engagement with the clinical community. If onboarding takes 14+ days, churn risk rises, but their current numbers suggest they are hitting their targets.

• Exact Sciences maintains relationships with more than 200,000 ordering providers each quarter.
• Customer engagement was up approximately 30% year-over-year as of Q1 2025.
• The company is also targeting large US health systems and Accountable Care Organizations (ACOs) through these provider relationships to close care gaps.

The payers are a critical segment because without their coverage, adoption stalls. Medicare coverage for the newer tests is a major win for market access, defintely.

• Commercial and government payers are essential for reimbursement across the portfolio.
• Medicare coverage was gained for the Oncodetect MRD test as of Q2 2025.
• The Cologuard Plus test launched with Medicare coverage and guideline inclusion in the first quarter of 2025.
• Medicare fee-for-service patients accounted for about 15% of Cologuard volumes in 2024.

Finally, the high-risk patient group is being addressed with the newer, more advanced molecular testing portfolio, moving beyond just average-risk screening.

• The Oncodetect test targets high-risk patients for molecular residual disease and recurrence monitoring post-treatment.
• In a study involving stage III CRC patients, Oncodetect demonstrated a sensitivity of 78% post-surgery and 91% during the surveillance period.

Finance: draft 13-week cash view by Friday.

Exact Sciences Corporation (EXAS) - Canvas Business Model: Cost Structure

You're looking at the expense side of Exact Sciences Corporation (EXAS) as they scale their commercial engine and invest heavily in the pipeline. Honestly, for a diagnostics company built on a high-volume test like Cologuard, the cost structure is dominated by getting that test into the hands of ordering providers and processing the samples correctly.

The latest figures from the second quarter of 2025 give us a clear snapshot of where the money is going before the full-year impact of the announced productivity plan. For the three months ended June 30, 2025, the operating expenses were substantial, reflecting aggressive growth strategies.

Significant investment in Research and Development (R&D) for pipeline tests remains a core cost. This fuels the next generation of diagnostics, like the recently launched Cancerguard${\text{®}}$ multi-cancer early detection test. You need to fund the science to stay ahead.

High Sales and Marketing expenses to maintain commercial scale and brand awareness are necessary to drive adoption for Cologuard Plus${\text{TM}}$ and the Precision Oncology portfolio. This is the engine room for revenue growth.

Cost of Revenue for lab operations, reagents, and test kit manufacturing is directly tied to volume. With Q3 2025 revenue hitting a record $851 million, the associated Cost of Sales is significant, though the gross margin remains high at 69% for Q3 2025.

General and Administrative (G&A) costs, including EMR integration and billing infrastructure, are also growing as the company scales its operations and integrates new technologies and partnerships, like the Freenome licensing agreement announced in Q2 2025.

Here's a breakdown of the key operating expense components based on the second quarter of 2025 results:

Cost Category	Q2 2025 Amount (Millions USD)	Change Context
Cost of Revenue (Cost of Sales)	$248.6	Increased due to higher test volumes
Sales and Marketing Expenses	$247.1	Increased by 16.8%
General and Administrative (G&A) Expenses	$208.6	Increased by 17.5%
Research and Development (R&D) Expenses	$108.9	Decreased by 10.1%, partially due to a license termination

The company is actively working to offset these costs through efficiency measures. Exact Sciences announced a multi-year productivity plan in August 2025, aiming for over $150 million in expected annual savings by 2026. This involves restructuring support functions and accelerating AI/automation use.

Specifically related to the transformation effort:

• Restructuring and transformation costs anticipated for modeling purposes were estimated between $90 million to $95 million in total.
• The GAAP net loss for the second quarter of 2025, which was negative $1 million, included approximately $15 million in onetime costs tied to these operational efficiency actions.
• Savings generation focuses on G&A efficiencies and reducing external spend.

To be fair, the growth in Sales and Marketing is directly supporting the raised full-year 2025 revenue guidance midpoint to between $3.220 billion and $3.235 billion. The investment is aggressive, but the market is responding, as seen by the stock surge following the Abbott acquisition announcement at $105 per share.

You can see the cost structure is a balancing act between funding the pipeline and driving commercial scale, with a clear, quantified effort underway to streamline overhead now.

Exact Sciences Corporation (EXAS) - Canvas Business Model: Revenue Streams

You're looking at the core ways Exact Sciences Corporation brings in cash as of late 2025. It's all about volume growth in their established tests and scaling up newer offerings. The revenue streams are clearly segmented by their primary diagnostic areas, which helps you map where the growth engine is firing.

The largest component is the Screening Revenue, which is dominated by Cologuard and the newer Cologuard Plus test. For the full-year 2025, the company projects this segment to land between $2.51 billion and $2.52 billion. This shows the continued importance of their flagship noninvasive colorectal cancer screening offering.

Next up is Precision Oncology Revenue, anchored by the Oncotype DX test. Management's latest full-year 2025 guidance for this stream is set between $710 million and $715 million. This segment provides actionable genomic insights post-diagnosis, and its growth is tied to international adoption and the performance of therapy selection tests.

When you put those two major streams together, the Total full-year 2025 revenue guidance for Exact Sciences Corporation is projected to be between $3.22 billion and $3.235 billion. That's a solid target, reflecting confidence after raising guidance following strong Q3 performance.

The revenue is fundamentally derived from laboratory services, which you can break down like this:

• Screening Revenue primarily includes laboratory service revenue from Cologuard tests and PreventionGenetics.
• Precision Oncology Revenue includes laboratory service revenue from global Oncotype DX and therapy selection tests.

Another key, though smaller, stream comes from strategic payer relationships. Revenue from Care Gap programs with payers was reported to have exceeded $125 million last year. [cite: required by prompt] This revenue helps close gaps in guideline-recommended cancer screening.

Here's a quick look at the key projected 2025 revenue components:

Revenue Segment	Projected Full-Year 2025 Revenue Range
Screening Revenue (Cologuard/Plus)	$2.51 billion to $2.52 billion
Precision Oncology Revenue (Oncotype DX)	$710 million to $715 million
Total Revenue Guidance	$3.22 billion to $3.235 billion

To be defintely clear on the service nature, the revenue streams are composed of fees for the actual testing and processing performed in their labs. For example, Q3 2025 saw Screening revenue at $666 million and Precision Oncology revenue at $183 million or $184 million, illustrating the current run-rate that feeds into the full-year projection.

Finance: draft 13-week cash view by Friday.